Know the Latest About COVID-19 Monoclonal Antibodies

Recent evidence and rising cases will renew focus on COVID-19 monoclonal antibodies...casirivimab/imdevimab (Regen-COV), etc.

Patients. Early data now suggest casirivimab/imdevimab reduces mortality in patients HOSPITALIZED due to COVID-19.

But it’s not authorized for these patients yet...and the dose showing benefit is over 6 times the current authorized dose.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote